US Bancorp’s Bicycle Therapeutics BCYC Stock Holding History

US Bancorp’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-300	Closed	-$7.47K	–	3981
2024 Q1	$7.47K	Buy	+300	New	+$6.37K	﹤0.01%	3424
2023 Q1	–	Sell	-234	Closed	-$6.93K	–	4093
2022 Q4	$6.93K	Hold	234	–	–	﹤0.01%	3409
2022 Q3	$5K	Sell	234 -149	-39%	-$3.54K	﹤0.01%	3574
2022 Q2	$6K	Buy	383 +149	+64%	+$3.14K	﹤0.01%	3505
2022 Q1	$10K	Sell	234 -137	-37%	-$6.4K	﹤0.01%	3362
2021 Q4	$23K	Sell	371 -9,618	-96%	-$531K	﹤0.01%	3026
2021 Q3	$416K	Sell	9,989 -2,752	-22%	-$96.3K	﹤0.01%	1616
2021 Q2	$387K	Buy	12,741 +167	+1%	+$5.05K	﹤0.01%	1680
2021 Q1	$376K	Sell	12,574 -499	-4%	-$12.9K	﹤0.01%	1636
2020 Q4	$235K	Buy	+13,073	New	+$252K	﹤0.01%	1810

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

US Bancorp's BCYC Position: Q2 2024 in Review

US Bancorp sold out of Bicycle Therapeutics (BCYC) in Q2 2024, closing a stake of 300 shares — an estimated $7.47K sold.

US Bancorp first reported a position in BCYC in Q4 2020 and held it in 10 quarters. The position peaked at $416K in Q3 2021. 107 funds tracked by Wall St. Rank hold BCYC as of Q2 2024.

US Bancorp reported no remaining Bicycle Therapeutics position as of Q2 2024 after selling out during the quarter.
US Bancorp sold 300 Bicycle Therapeutics shares in Q2 2024, an estimated $7.47K.
US Bancorp first reported a position in Bicycle Therapeutics in Q4 2020 and held it in 10 quarters.
US Bancorp's Bicycle Therapeutics position peaked at $416K in Q3 2021.
107 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2024.

Based on US Bancorp's 13F filing for Q2 2024, filed 7 Aug 2024.